Skip to content
Clinical ResearchResearch compound

RAD‑140 (Testolone)

An experimental muscle-building SARM; not approved as a medicine, severe liver damage has been reported, banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

RAD-140 (Testolone) vial

Related comparisons

Ostarine vs RAD-140

DETAILED OVERVIEW

What is RAD-140 (Testolone)?

RAD-140 (Testolone) is an experimental compound, a so-called SARM (selective androgen receptor modulator), that mainly imitates the effect of testosterone in muscle and bone. It has not been approved as a medicine anywhere: only a few small studies have been done in humans, the results were not convincing enough, and development was stopped. It is sold as a research chemical and is banned in competitive sport all year round.

Its most serious known risk is liver damage: six documented cases have been described, some of them close to needing a liver transplant. It strongly suppresses the body's own testosterone production, which can cause tiredness, lower sex drive and shrinking testicles, and fertility drops temporarily. It lowers HDL cholesterol (the beneficial kind), and in women it can cause irreversible masculinization. It must not be used in pregnancy or breastfeeding, because it can masculinize the baby.

Mechanism

Non-steroidal selective AR modulator (anilide). Strong AR agonist in muscle + bone, weaker in prostate.

Anabolic activity (Miller 2011)

About 80% of testosterone's effect in muscle, about 30% in the prostate

Half-life

~16-20 h (oral)

Onset

1-2 weeks (anecdotal strength gain)

Legal status

Never an Rx (Phase II stalled). UGL market 'research chemical'. USA Schedule III analog in some states from 2018. WADA-banned.

Data console

Lab data

Androgenic:Anabolic~80:30 (muscle:prostate selectivity ratio Miller 2011 PMID 21953468 – AR binding assay vs rat bioassay). NOT a classical Test-proportional androgenic number.
AR bindingNon-steroidal SARM, AR-binding affinity ~80%…
Active half-life~16-20 h
Detection windowUrinary: 3-6 weeks RAD-140 metabolites by LC-MS/MS (WADA-accredited, official target since 2019). Longer than classical AAS (slow clearance).
AromatizationNO – RAD-140 non-steroidal, NOT a CYP19 substrate. E2 does not rise (Bhasin 2012 PMID 22573713). This is a SARM advantage: no gyno risk via the E2 mechanism.
HepatotoxicityHIGH – 6 documented hepatocellular injury case reports 2017-2020 (Hilal 2020 PMID 32492288, Barbara 2020 PMID 33068441). ALT/AST >10x normal, some near transplant-level. Hepatotoxicity mechanism mitochondrial dysfunction + reactive metabolite (Solomon 2019 PMID 31077635 review). TUDCA + milk-thistle + monthly ALT/AST testing ABSOLUTELY mandatory.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Hepatotoxicity (drug-induced liver injury, DILI): as an oral SARM, multiple documented case reports show ALT/AST elevations >10x, cholestatic/hepatocellular jaundice, and acute liver failure in severe cases.
  • HPTA suppression: strong suppression of endogenous testosterone, LH and FSH production (~80% after 6-8 weeks), which can cause fatigue, low libido and testicular atrophy.
  • Adverse lipid shift: marked drop in HDL (good) cholesterol (~30-50%), raising long-term cardiovascular risk.
  • Reduced fertility: temporary suppression of spermatogenesis; full HPTA recovery may take 3-6 months after the cycle.
  • Mood and sleep disturbances: anecdotally increased aggression, irritability and insomnia, with strongly individual severity.
  • Androgenic effects: hair thinning/androgenic alopecia in predisposed users, increased sebum and acne.
  • Slow clearance: with a ~16-20 hour half-life, the compound cannot be cleared quickly if adverse effects appear, and effects can persist for days.

Contraindications · 7

  • Any pre-existing liver disease or already elevated ALT/AST/bilirubin: absolute contraindication given the documented DILI risk.
  • Concurrent alcohol use or other hepatotoxic agents (other oral SARMs, 17-alpha-alkylated steroids, high-dose paracetamol): cumulative liver burden.
  • Pregnancy and breastfeeding: risk of fetal virilization from androgenic activity, absolute contraindication.
  • Women, especially at higher doses: risk of irreversible virilization (voice deepening, hirsutism, clitoral enlargement).
  • Planned fatherhood in the near term: HPTA suppression and recovery of spermatogenesis can take up to 3-6 months.
  • Pre-existing dyslipidemia or cardiovascular disease: HDL reduction further worsens the lipid profile and CV risk.
  • Competitive athletes: banned year-round by WADA (S1.2 other anabolic agents), with a 3-6 week urinary detection window.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about RAD‑140 (Testolone)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.